tiprankstipranks
Riken Vitamin Co., Ltd. (JP:4526)
:4526
Japanese Market
Want to see JP:4526 full AI Analyst Report?

Riken Vitamin Co., Ltd. (4526) AI Stock Analysis

0 Followers

Top Page

JP:4526

Riken Vitamin Co., Ltd.

(4526)

Select Model
Select Model
Select Model
Outperform 77 (OpenAI - 5.2)
Rating:77Outperform
Price Target:
¥3,723.00
▲(15.98% Upside)
Action:Upgraded
Date:08/17/26
Overall score reflects a strong, low-leverage balance sheet and constructive price momentum, supported by reasonable valuation and a solid dividend yield. The key risk tempering the score is the recent deterioration in cash flow conversion and softer margins versus the 2024–2025 peak, which raises questions about near-term earnings and cash durability.
Positive Factors
Conservative Balance Sheet
Very low leverage and a growing equity base reduce financial risk and preserve flexibility for investment, procurement needs and potential downturns. This strengthens the company’s ability to sustain operations while funding its food and materials businesses.
Negative Factors
Sharp Free Cash Flow Decline
The steep reduction in free cash flow weakens cash conversion and may reflect higher reinvestment or working-capital requirements. If sustained, it could constrain internally funded growth and reduce the durability of shareholder distributions.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage and a growing equity base reduce financial risk and preserve flexibility for investment, procurement needs and potential downturns. This strengthens the company’s ability to sustain operations while funding its food and materials businesses.
Read all positive factors

Riken Vitamin Co., Ltd. (4526) vs. iShares MSCI Japan ETF (EWJ)

Riken Vitamin Co., Ltd. Business Overview & Revenue Model

Company Description
Riken Vitamin Co., Ltd., based in Tokyo, Japan, operates across several key sectors: food ingredients, food applications, healthcare, and chemicals. The company provides a diverse portfolio of food additives, including emulsifiers used in a wide a...
How the Company Makes Money
Riken Vitamin makes money primarily by manufacturing and selling products in two broad categories: (1) food-related products and ingredients and (2) industrial/chemical functional materials. In the food domain, revenue is generated from supplying ...

Riken Vitamin Co., Ltd. Financial Statement Overview

Summary
Financials are solid overall: steady revenue growth and acceptable profitability (2026 gross margin ~31%, net margin ~7%), supported by a very conservative balance sheet (debt-to-equity ~0.09). The main drag is weaker cash conversion and a sharp decline in free cash flow in 2026 (~¥0.9B vs ~¥3.1B in 2025 and ~¥7.4B in 2024), alongside margin normalization versus 2024–2025.
Income Statement
74
Positive
Balance Sheet
86
Very Positive
Cash Flow
58
Neutral
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue98.18B96.30B95.58B91.48B88.75B79.23B
Gross Profit30.14B29.77B31.27B29.89B27.24B25.57B
EBITDA11.90B11.58B16.04B15.35B11.71B24.23B
Net Income7.08B7.04B9.39B8.76B6.41B21.58B
Balance Sheet
Total Assets117.34B116.39B113.00B118.78B105.22B102.66B
Cash, Cash Equivalents and Short-Term Investments17.91B20.07B22.30B23.38B19.16B17.30B
Total Debt7.40B7.14B9.98B16.09B14.60B17.57B
Total Liabilities32.94B33.01B33.80B42.13B33.85B36.12B
Stockholders Equity84.36B83.34B79.16B76.61B71.34B66.52B
Cash Flow
Free Cash Flow0.00925.00M3.12B7.42B5.67B3.44B
Operating Cash Flow0.005.96B7.89B10.45B7.83B6.82B
Investing Cash Flow0.001.75B353.00M-554.00M-2.03B-3.66B
Financing Cash Flow0.00-8.04B-9.96B-7.08B-4.58B-7.57B

Riken Vitamin Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3210.00
Price Trends
50DMA
3164.34
Positive
100DMA
3003.87
Positive
200DMA
2961.11
Positive
Market Momentum
MACD
70.21
Negative
RSI
73.89
Negative
STOCH
84.40
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4526, the sentiment is Positive. The current price of 3210 is below the 20-day moving average (MA) of 3252.25, above the 50-day MA of 3164.34, and above the 200-day MA of 2961.11, indicating a bullish trend. The MACD of 70.21 indicates Negative momentum. The RSI at 73.89 is Negative, neither overbought nor oversold. The STOCH value of 84.40 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4526.

Riken Vitamin Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
¥78.33B14.243.43%3.11%-17.81%
66
Neutral
¥12.79B10.793.94%1.89%-32.59%
65
Neutral
¥379.58B15.292.42%1.89%227.30%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
61
Neutral
¥34.39B10.524.28%2.06%-23.96%
60
Neutral
¥5.07T37.8218.38%0.94%6.72%83.84%
57
Neutral
¥392.16B29.081.45%9.93%1562.32%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4526
Riken Vitamin Co., Ltd.
3,435.00
623.24
22.17%
JP:2802
Ajinomoto Co
5,441.00
1,423.15
35.42%
JP:2264
Morinaga Milk Industry Co., Ltd.
1,158.50
354.28
44.05%
JP:2607
Fuji Oil Holdings, Inc.
4,555.00
860.25
23.28%
JP:2927
AFC-HD AMS Life Science Co., Ltd.
901.00
52.30
6.16%
JP:3139
Lacto Japan Co., Ltd.
3,445.00
-399.24
-10.39%

Riken Vitamin Co., Ltd. Corporate Events

Riken Vitamin Lifts Q1 Sales, Expands Capacity as Overseas Business Returns to Profit
Aug 7, 2026
Riken Vitamin reported an 8.1% year-on-year rise in first-quarter net sales to ¥25.1 billion, with growth across domestic food, domestic chemical, and overseas segments, while operating profit slipped 4.9% due mainly to higher costs and a &#1...
Riken Vitamin Lifts Sales but Sees Margin Pressure in Q1, Keeps Dividend Outlook Steady
Aug 7, 2026
Riken Vitamin Co., Ltd. reported consolidated net sales of ¥25.1 billion for the quarter ended June 30, 2026, up 8.1% year on year, while operating profit slipped 4.9% to ¥2.25 billion and ordinary profit was essentially flat, resulting ...
Riken Vitamin Advances Share Buyback, Acquires Over 350,000 Shares
Aug 3, 2026
Riken Vitamin Co., Ltd. has reported progress on its ongoing share buyback program, acquiring 192,500 shares of common stock on the Tokyo Stock Exchange between July 1 and July 31, 2026, at a total cost of about 606 million yen. This activity form...
Riken Vitamin Reports Progress on Share Buyback Program
Jul 1, 2026
Riken Vitamin Co., Ltd. has disclosed the progress of its share buyback program, reporting the acquisition of 165,800 shares of its common stock on the Tokyo Stock Exchange between June 1 and June 30, 2026, at a total cost of approximately 487 mil...
Riken Vitamin Raises Annual Dividend as Payout Climbs to ¥110 per Share
May 20, 2026
Riken Vitamin Co., Ltd. will pay a year-end dividend of ¥55 per share for the fiscal year ended March 31, 2026, matching its latest forecast and exceeding the prior year’s ¥53.50. The total year-end payout amounts to ¥1,615 mi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 17, 2026